title: Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012".
abstract: Recent insights into the genetic and somatic aberrations have initiated a new era of rapidly evolving targeted and immune-based treatments for melanoma. After decades of unsuccessful attempts to finding a more effective cure in the treatment of melanoma now we have several drugs active in melanoma. The possibility to use these drugs in combination to improve responses to overcome the resistance, to potentiate the action of immune system with the new immunomodulating antibodies, and identification of biomarkers that can predict the response to a particular therapy represent new concepts and approaches in the clinical management of melanoma. The third "Melanoma Research: "A bridge from Naples to the World" meeting, shortened as "Bridge Melanoma Meeting" took place in Naples, December 2 to 4th, 2012. The four topics of discussion at this meeting were: advances in molecular profiling and novel biomarkers, combination therapies, novel concepts toward integrating biomarkers and therapies into contemporary clinical management of patients with melanoma across the entire spectrum of disease stage, and the knowledge gained from the biology of tumor microenvironment across different tumors as a bridge to impact on prognosis and response to therapy in melanoma. This international congress gathered more than 30 international faculty members who in an interactive atmosphere which stimulated discussion and exchange of their experience regarding the most recent advances in research and clinical management of melanoma patients.
authors.affiliation: Istituto Nazionale Tumori, Fondazione "G, Pascale", Naples, Italy. paolo.ascierto@gmail.com
authors.forename: Paolo A
authors.initials: PA
authors.lastname: Ascierto
authors.forename: Antonio M
authors.initials: AM
authors.lastname: Grimaldi
authors.forename: Nicolas
authors.initials: N
authors.lastname: Acquavella
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Borgognoni
authors.forename: Luana
authors.initials: L
authors.lastname: Calabrò
authors.forename: Natale
authors.initials: N
authors.lastname: Cascinelli
authors.forename: Alessandra
authors.initials: A
authors.lastname: Cesano
authors.forename: Michele
authors.initials: M
authors.lastname: Del Vecchio
authors.forename: Alexander M
authors.initials: AM
authors.lastname: Eggermont
authors.forename: Mark
authors.initials: M
authors.lastname: Faries
authors.forename: Soldano
authors.initials: S
authors.lastname: Ferrone
authors.forename: Bernard A
authors.initials: BA
authors.lastname: Fox
authors.forename: Thomas F
authors.initials: TF
authors.lastname: Gajewski
authors.forename: Jérôme
authors.initials: J
authors.lastname: Galon
authors.forename: Sacha
authors.initials: S
authors.lastname: Gnjatic
authors.forename: Helen
authors.initials: H
authors.lastname: Gogas
authors.forename: Mohammed
authors.initials: M
authors.lastname: Kashani-Sabet
authors.forename: Howard L
authors.initials: HL
authors.lastname: Kaufman
authors.forename: James
authors.initials: J
authors.lastname: Larkin
authors.forename: Roger S
authors.initials: RS
authors.lastname: Lo
authors.forename: Alberto
authors.initials: A
authors.lastname: Mantovani
authors.forename: Kim
authors.initials: K
authors.lastname: Margolin
authors.forename: Cornelis
authors.initials: C
authors.lastname: Melief
authors.forename: Grant
authors.initials: G
authors.lastname: McArthur
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Palmieri
authors.forename: Igor
authors.initials: I
authors.lastname: Puzanov
authors.forename: Antoni
authors.initials: A
authors.lastname: Ribas
authors.forename: Barbara
authors.initials: B
authors.lastname: Seliger
authors.forename: Jeff
authors.initials: J
authors.lastname: Sosman
authors.forename: Peter
authors.initials: P
authors.lastname: Suenaert
authors.forename: Ahmad A
authors.initials: AA
authors.lastname: Tarhini
authors.forename: Giorgio
authors.initials: G
authors.lastname: Trinchieri
authors.forename: Fernando
authors.initials: F
authors.lastname: Vidal-Vanaclocha
authors.forename: Ena
authors.initials: E
authors.lastname: Wang
authors.forename: Gennaro
authors.initials: G
authors.lastname: Ciliberto
authors.forename: Nicola
authors.initials: N
authors.lastname: Mozzillo
authors.forename: Francesco M
authors.initials: FM
authors.lastname: Marincola
authors.forename: Magdalena
authors.initials: M
authors.lastname: Thurin
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor; D002986:Clinical Trials as Topic; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008495:Medical Oncology / Q000639:trends; D008545:Melanoma / Q000175:diagnosis* / Q000378:metabolism / Q000628:therapy*; D009154:Mutation; D011379:Prognosis; D012878:Skin Neoplasms / Q000175:diagnosis* / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor